HEALTH

Oncologists favor biosimilar adoption, Decision Resources finds

BY Alaric DeArment

BURLINGTON, Mass. While biosimilars promise to provide therapies for a wide range of diseases, their biggest fans may come from cancer specialists, according to a new report.

Healthcare market research firm Decision Resources found in a report that oncologists would be the most aggressive in adopting biosimilars compared with other specialists because of their lower clinical trial requirements. According to research, oncologists in the United States will adopt biosimilars faster than their European counterparts because they will require fewer and shorter phase-3 clinical trials before they feel comfortable prescribing them.

The firm expected biosimilars of granulocyte colony-stimulating factor, as well as biosimilars of monoclonal antibody therapies used to treat cancer, to reduce brand sales by more than $7 billion in 2019 in the United States, Japan, the United Kingdom, France, Germany, Italy and Spain, which Decision Resources collectively refers to as the “EU5.”

“Because of patent expiries and more-established regulatory pathways for approving biosimilars in Europe, most biosimilar [monoclonal antibodies] will launch in the EU5 before the United States,” Decision Resources analyst Cindy Fung said. “As a result, U.S. physicians will likely benefit from clinical experience in European markets that will increase their rate of adopting these agents.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Sun Pharma gets FDA approval for ALS generic

BY Alaric DeArment

MUMBAI, India The Food and Drug Administration has approved a generic version of a drug for a devastating muscular disorder.

 

Sun Pharmaceutical Industries announced Tuesday the approval of riluzole hydrochloride in the 50-mg strength. The tablets are used to treat amyotrophic lateral sclerosis or ALS, also known as Lou Gehrig’s disease.

 

 

The drug is a generic version of Sanofi-Aventis’ Rilutek, which has sales of around $50 million, according to Sun.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Cirrus targets ear-ringing with Tinnitex

BY Allison Cerra

COLD SPRING HARBOR, N.Y. Cirrus Healthcare Products has expanded its ear care offerings with a new product, slated to hit retail shelves in spring 2011.

Tinnitex is the first and only earplug to help relieve tinnitus, a condition that causes ringing in the ears, the company said. According to the Journal of Clinical Nursing, more than 50 million Americans suffer from tinnitus.

“Tinnitex gives the suffering consumer an option to the inconvenience of ear drops or the excessive amount of pills that consumers are tired of taking. The Tinnitex earplug is easy to apply and comfortable to wear and, at about $10 at retail for six pairs, provides affordable relief,” said Cirrus CEO Drew O’Connell.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?